| Identification | Back Directory | [Name]
5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide | [CAS]
2932264-95-2 | [Synonyms]
5-[[4-[4-[(Dimethylamino)methyl]-3-methyl-1-pyrazolyl]-2-pyrimidinyl]amino]-N,1-dimethyl-1H-indazole-3-carboxamide | [Molecular Formula]
C21H25N9O | [MOL File]
2932264-95-2.mol | [Molecular Weight]
419.48 |
| Chemical Properties | Back Directory | [density ]
1.354±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
12.925±0.46(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers[1]. | [in vivo]
Syk-IN-4 exhibits moderate oral bioavailability (60%) following oral administration (1 mg/kg) in male Hans Wistar rats[1].
Syk-IN-4 exhibits high plasma clearance (151 mL/min/kg) combined with large volumes of distribution (1.0 L/kg respectively) following i.v. administration (0.5 mg/kg) in male Hans Wistar rats[1]. | [References]
[1] Neil P Grimster, et al. Optimization of a Series of Potent, Selective and Orally Bioavailable SYK Inhibitors. Bioorg Med Chem Lett. 2020 Jul 24;127433. DOI:10.1016/j.bmcl.2020.127433 |
|
|